Prognostic value of NFκB, CD9, and VEGF in gastrointestinal stromal tumors

Abstract

Aim of the studyGastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of the gastrointestinal system. We aimed to determine whether nuclear transcription factor κB (NF-κB), CD9 and vascular endothelial growth factor (VEGF) have prognostic value in patients with GIST.Material and methodsThirty-five patients with GIST, who were diagnosed in the Pathology Department of Erciyes University, were included in the study. Cases were classified based on the 2002 NIH consensus. CD9, VEGF, and NF-κB immunohistochemistry were applied to GIST cases positive for CD117 and CD34, which are used to evaluate GISTs immunohistochemically.ResultsAlthough there are no statistically significant differences between NF-κB (p = 0.329), CD9 (p = 0.269), and VEGF (p = 0.372) and risk groups, 79.22% of cases that stained positive for NF-κB, 81% of cases that stained positive for CD9, and 80% of cases that stained positive of VEGF were in the high risk group.ConclusionsIt was found that NF-κB, CD9, and VEGF, which are important in predicting behaviors of other malign tumors, were expressed at high rates in high risk group GISTs. This can be used to determine prognosis with tumor diameter, mitosis rate under 50 BBS, Ki-67 proliferation index and other parameters.

Clinical presentation, management and outcomes of gastrointestinal stromal tumors

“…c-KIT gene mutation occurs in vast majority of GIST cases (more than 80% of GISTs) followed by platelet derived growth factor receptor a (PDGFRA) mutations. c-KIT and PDGFRA genes are located in the fourth chromosome in humans [5]. CD117, a protein encoded by the c-KIT gene, is an important marker in the diagnosis of GIST.…”

Improved understanding of gastrointestinal stromal tumors biology as a step for developing new diagnostic and therapeutic schemes (Review)

“…VEGF expression is frequently increased in GISTaccounted positively for 60-80% of all studied cases (22)(23)(24). Null or weak expression of VEGF is associated with better prognosis [higher progression-free survival (PFS) and OS], independently of the tumor genotype.…”

Gastrointestinal Stromal Tümörlerin Demografik, Histopatolojik, ve İmmünohistokimyasal Karakteristik Bulguları: Tek Merkez Çalışması

“…1,11 In this series, Clinical and histopathological fi ndings and the immunohistochemical staining panel are used in the diagnosis, classifi cation, and prognosis determination of GISTs. In the immunohistochemical panel, vimentin, SMA,desmin, S100, CD34, CD117, and Ki 67 are used [24][25][26] . In the present study, the same antibodies were evaluated on the immunohistochemical panel.…”